➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
AstraZeneca
Express Scripts
Merck
Medtronic
Johnson and Johnson

Last Updated: May 29, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for GSK2982772


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the drug development status for GSK2982772?

GSK2982772 is an investigational drug.

There have been 9 clinical trials for GSK2982772. The most recent clinical trial was a Phase 1 trial, which was initiated on November 1st 2016.

The most common disease conditions in clinical trials are Autoimmune Diseases, Psoriasis, and Inflammatory Bowel Diseases. The leading clinical trial sponsors are GlaxoSmithKline, Clinical Unit at Cambridge (Addenbrooks), and Quotient Sciences.

There are six US patents protecting this investigational drug and one hundred and one international patents.

Recent Clinical Trials for GSK2982772
TitleSponsorPhase
A Study to Evaluate the Benefit and Safety of GSK2982772 in Moderate to Severe Psoriasis ParticipantsGlaxoSmithKlinePhase 1
A Study to Investigate the Pharmacokinetics of Modified Release (MR) Prototype Coated Tablet Formulations of GSK2982772Quotient SciencesPhase 1
A Study to Investigate the Pharmacokinetics of Modified Release (MR) Prototype Coated Tablet Formulations of GSK2982772GlaxoSmithKlinePhase 1

See all GSK2982772 clinical trials

Clinical Trial Summary for GSK2982772

Top disease conditions for GSK2982772
Top clinical trial sponsors for GSK2982772

See all GSK2982772 clinical trials

US Patents for GSK2982772

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
GSK2982772   Start Trial Crystalline forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-- yl)-4H-1,2,4-triazole-3-carboxamide GlaxoSmithKline Intellectual Property Development Limited (Brentford, Middlesex, GB)   Start Trial
GSK2982772   Start Trial Heterocyclic amides as kinase inhibitors GlaxoSmithKline Intellectual Property Development Limited (Brentford, Middlesex, GB)   Start Trial
GSK2982772   Start Trial Heterocyclic amides as kinase inhibitors GlaxoSmithKline Intellectual Property Development Limited (Brentford, Middlesex, GB)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
Express Scripts
McKesson
Medtronic
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.